Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

16.5K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.5K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

94
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced circulating FABP2 in patients with moderate to severe COVID-19 may indicate enterocyte functional change rather than cell death.

Scientific reports·2022
Same author

Lombardy diagnostic and therapeutic network of thrombotic microangiopathy.

Orphanet journal of rare diseases·2022
Same author

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.

ESMO open·2022
Same author

Evaluation of procoagulant imbalance in Cushing's syndrome after short- and long-term remission of disease.

Journal of endocrinological investigation·2021
Same author

Evolution of Haemophilia Care in Europe: 10 years of the principles of care.

Orphanet journal of rare diseases·2020
Same author

COVID-19 Network: the response of an Italian Reference Institute to research challenges about a new pandemia.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020
Same journal

Male Range of Motion Norms in the Haemophilia Joint Health Score Underrepresent the Severity of Joint Damage in Females.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Physical Activity and Sedentary Behaviour in Children With Haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Ten-year Demographic and Clinical Characterisation of People With Haemophilia: The Colombian Registry Experience.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Exploratory Claims-Based Assessment of Diagnosed and Potentially Undiagnosed von Willebrand Disease in Japan.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Use of an Oral Health-Related Quality of Life Instrument to Measure Unmet Dental Care Needs in Adults With Inherited Bleeding Disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Clinical Factors for Predicting Synovial Hypertrophy in Early Haemophilic Arthropathy on Prophylaxis: A Cross-Sectional Study of Patient- and Joint-Level Analyses Using Musculoskeletal Ultrasound.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
See all related articles

Related Experiment Video

Updated: Mar 18, 2026

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

13.1K

Genomic approaches to bleeding disorders.

F Peyvandi1,2, C P M Hayward3

  • 1Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|July 14, 2016
PubMed
Summary
This summary is machine-generated.

Genetic diagnosis for rare bleeding and platelet disorders is advancing, with DNA sequencing identifying mutations. New genomic technologies are crucial for cases lacking identified genetic defects, improving diagnostic infrastructure.

Keywords:
genotypingplatelet disordersrare bleeding disorders

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K
Characterization of Blood Outgrowth Endothelial Cells BOEC from Porcine Peripheral Blood
08:02

Characterization of Blood Outgrowth Endothelial Cells BOEC from Porcine Peripheral Blood

Published on: January 6, 2022

2.1K

Related Experiment Videos

Last Updated: Mar 18, 2026

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

13.1K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K
Characterization of Blood Outgrowth Endothelial Cells BOEC from Porcine Peripheral Blood
08:02

Characterization of Blood Outgrowth Endothelial Cells BOEC from Porcine Peripheral Blood

Published on: January 6, 2022

2.1K

Area of Science:

  • Genetics
  • Hematology
  • Molecular Biology

Background:

  • Genetic diagnosis of common inherited bleeding disorders like hemophilia A and B is well-established.
  • Understanding of rare bleeding disorders and platelet disorders genetics is less advanced.
  • Rare bleeding disorders are typically autosomal recessive, while some platelet disorders are autosomal dominant.

Purpose of the Study:

  • To review the current state of genetic diagnosis for inherited bleeding and platelet disorders.
  • To highlight the utility of DNA sequencing in identifying causative mutations.
  • To discuss the potential of new genomic technologies for undiagnosed cases.

Main Methods:

  • DNA sequencing for identifying mutations in coding regions and splice sites.
  • Review of genetic characterization for inherited bleeding and platelet disorders.
  • Discussion of next-generation sequencing and other genomic technologies.

Main Results:

  • DNA sequencing has been effective for many inherited bleeding and platelet disorders.
  • A significant percentage (5-10%) of severe clotting factor deficiencies lack identified genetic defects.
  • Genetic characterization of inherited platelet disorders was previously limited to prevalent conditions.

Conclusions:

  • Advanced genomic technologies, including next-generation sequencing, are essential for diagnosing patients with unidentified genetic defects.
  • These new methods necessitate significant bioinformatics analysis and infrastructure upgrades.
  • Improved genetic diagnostic approaches are critical for rare bleeding and platelet disorders.